Abhishek, A17806
Purpose:To compare the efficacy and safety of intravitreal triamcinolone acetonide and dexamethasone (IVD) (0.7 mg),Ozurdex in the treatment of macular oedema secondary to NICRVO over 6 months.
Methods: prospective randomized trial,20 patients treated with IVTA (1.0 mg) and 20 with IVD (0.7 mg). Both groups were compared with regard to best-corrected visual acuity (BCVA), central macular thickness (CMT) on OCT, slit-lamp biomicroscopy and FFA, IOP,no.of injections and adverse events.
Results:Follow up period-6 months. BCVA improved,CMT decreased significantly within both groups equally. The no. of patients with increased IOP and iatrogenic cataract were significantly greater in the IVTA group.
Conclusion:Equivalent benefit of IVD and IVTA but reduced risk of cataract and IOP elevation would favour use of IVD over IVTA. As IVD is 400 times costlier than IVTA the final decision to use either drug rests with the clinician and patient after careful consideration of risk,benefit and cost